BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, April 26, 2026
Home » Blogs » BioWorld MedTech Perspectives » Fee diversion alive and well in H.R. 1249

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology / Patents

Fee diversion alive and well in H.R. 1249

June 22, 2011
By Mark McCarty

Those with a keen eye trained on the patent reform bill now under consideration in the House of Representatives might universally hold a dim view of fee diversion even if they see first-to-file and the prior user defense through profoundly different lenses. The problem is that the manager's mark for H.R. 1249 as of June 20 includes language that will put the fees paid by patent, trademark and copyright applicants right back into the hands of appropriators, who will have a tough time avoiding the urge to raid the cookie jar in a fiscal environment in which cookies are increasingly scarce.

The newest iteration of H.R. 1249 includes the language, “there is established in the Treasury a Patent and Trademark Fee Reserve Fund,” which will be filled with the proceeds collected in excess of the amounts appropriated to the U.S. Patent and Trademark Office in a given fiscal year. This new feature of H.R. 1249 provides that the monies in question “shall be made available until expended only for obligation and expenditure by” PTO “to the extent and in the amounts provided in appropriations Acts.”

So as the saying goes, the Appropriator giveth and the Appropriator taketh away. Or as some on Capitol Hill like to say, “there are legislators and then there are appropriators.”

It's not hard to understand why the House Appropriations Committee wants to avoid the appearance of favoritism, but the conceptual construct underlying the idea of ending diversion of PTO's fees into the Treasury's general fund is that innovation creates job and PTO needs more money to clear the patent backlog, which is presumed to be chock-full of job-creating innovation. Therefore, you have to let PTO keep the fees it collects from inventors if you want intellectual property to play a meaningful role in bringing the economy back to life. I have not heard the argument that the $50 million the Treasury would lose to PTO would be at least offset by an increase in tax revenues, but any such effect might not be felt for a couple of years, which might seem like an eternity to those trying to keep the U.S. government from ending up with the kind of credit rating now enjoyed by Greece and Ireland.

Still, the casual observer has to wonder how many small cuts to the corpus will yield a corpse. First-to-file is not universally popular, and the purportedly offsetting prior user defense is obnoxious to a far greater number. Is there any need for this bill if it allows appropriators to dive into the PTO piggy bank any time they want?

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 24, 2026.
  • Boy cupping ear with soundwave graphic

    A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

    BioWorld
    Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
  • Illustration of a tumor

    Detecting the invisible: minimal residual disease at AACR 2026

    BioWorld Science
    Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
  • Illustration of metastatic cancer

    At AACR: Epigenetic fingerprints in metastases track tumor origin

    BioWorld
    When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
  • Illustration of human face that looks abstract and digital

    AACR 2026: The age of agentic AI in oncology

    BioWorld Science
    New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing